Suppr超能文献

静脉注射硫酸镁:在直接经皮冠状动脉介入治疗中预防造影剂肾病的新方法。

Intravenous magnesium sulfate: new method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention.

作者信息

Firouzi Ata, Maadani Mohsen, Kiani Reza, Shakerian Farshad, Sanati Hamid Reza, Zahedmehr Ali, Nabavi Seyedabbas, Heidarali Mona

机构信息

Department of Interventional Cardiology, Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.

出版信息

Int Urol Nephrol. 2015 Mar;47(3):521-5. doi: 10.1007/s11255-014-0890-z. Epub 2014 Dec 5.

Abstract

BACKGROUND

Contrast-induced acute kidney injury (CI-AKI) is an adverse consequence of percutaneous coronary interventions which results in significant morbidity and mortality and adds to the costs of diagnostic and interventional cardiology procedures. Various pathophysiological mechanisms have been proposed for CI-AKI and various agents tested for its prevention. There is currently a general agreement that adequate pre-procedural hydration constitutes the cornerstone of prevention, yet there are reports of the use of some other agents with various efficacies. We prospectively tested IV magnesium sulfate (Mg) for CI-AKI prevention.

METHOD AND DESIGN

This study is a prospective, randomized, open-labeled, single-center clinical trial. We randomly assigned 122 consecutive patients to two groups. The first group was the control group with routine treatment (n = 64), and second group was the study group with routine treatment plus IV magnesium sulfate 1 g just before the procedure (n = 62). Serum creatinine was measured before the procedure and 2 days after the procedure. The primary end point was the occurrence of CI-AKI within 48 h. CI-AKI was defined as 0.5 mg/dl or more increase in serum creatinine or 25% or more increase above baseline serum creatinine. There was no difference in definition if both of these parameters were present.

RESULTS

The control and study groups were comparable in the overall predicted risk of CI-AKI. Also, the type and volume of the contrast were not significantly different between the two groups. Following angioplasty, CI-AKI occurred in 17 (26.6%) patients in the control group and nine (14.5%) patients in the study group; there was a significant reduction in CI-AKI in the study group (P = 0.01). Additionally, there was no mortality or a need for hemodialysis in either group.

CONCLUSION

In primary PCI patients, the prophylactic use of intravenous Mg can be recommended to be added to traditional hydration for CI-AKI prevention.

摘要

背景

造影剂诱导的急性肾损伤(CI-AKI)是经皮冠状动脉介入治疗的一种不良后果,会导致显著的发病率和死亡率,并增加诊断和介入心脏病学手术的成本。针对CI-AKI已提出了各种病理生理机制,并对多种预防药物进行了测试。目前普遍认为,术前充分水化是预防的基石,但也有使用其他具有不同疗效药物的报道。我们前瞻性地测试了静脉注射硫酸镁(Mg)预防CI-AKI的效果。

方法与设计

本研究是一项前瞻性、随机、开放标签、单中心临床试验。我们将122例连续患者随机分为两组。第一组为接受常规治疗的对照组(n = 64),第二组为在手术前接受常规治疗加静脉注射1 g硫酸镁的研究组(n = 62)。在手术前和手术后2天测量血清肌酐。主要终点是48小时内CI-AKI的发生情况。CI-AKI定义为血清肌酐升高0.5 mg/dl或以上,或高于基线血清肌酐25%或以上。如果这两个参数都存在,则定义无差异。

结果

对照组和研究组在CI-AKI的总体预测风险方面具有可比性。此外,两组之间造影剂的类型和用量没有显著差异。血管成形术后,对照组有17例(26.6%)患者发生CI-AKI,研究组有9例(14.5%)患者发生CI-AKI;研究组CI-AKI发生率显著降低(P = 0.01)。此外,两组均无死亡病例或需要进行血液透析的情况。

结论

在接受直接经皮冠状动脉介入治疗的患者中,建议在传统水化治疗的基础上预防性使用静脉注射Mg以预防CI-AKI。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验